Canada: Pharmacapsules @ Gowlings - December 2007

Last Updated: December 10 2007

Edited by Jennifer Wilkie and Chantal Saunders


  • Managing Health Claims For Foods in Canada - Discussion Paper, 2007
  • EU, US Regulators Ease Process for Orphan Drugs
  • Alliance Proposes New Wait Time Benchmarks
  • Health Canada Update Notice on Registration and Disclosure of Clinical Trial Information
  • Update on the Comprehensive Review of the Special Access Programme
  • Recent Cases

Managing Health Claims For Foods In Canada - Discussion Paper, 2007

Article by Roger Tam

Health Canada released a discussion paper on November 30, 2007 entitled "Managing Health Claims for Foods in Canada - Discussion Paper, 2007" for the purpose of examining possible changes to the current framework for managing health claims on foods. The discussion paper notes that while consumers generally tend to view health claims as similarly credible, there are significant differences in regulatory requirements between rigorous risk reduction claims ("A healthy diet with adequate calcium and vitamin D, and regular physical activity, help to achieve strong bones and may reduce the risk of osteoporosis") and maintenance claims ("Vitamin A aids in the maintenance of night vision"). Current guidelines are found in the 2003 Guide to Food Labelling and Advertising.

The purpose of the discussion paper is to respond to the increasing interest in the health value of foods, and for more efficient and transparent processes for the approval of health claims. Similar reviews are being conducted in the European Union, Australia, New Zealand and the U.S.

Issues raised in the discussion paper include :

  • Efficiency and openness of the assessment process
  • The need for international standardization
  • Requisite standards for scientific substantiation of claims
  • Interphase between foods and natural health products
  • Permissible health claims and how these should be delivered
  • Improving consumer understanding of health claims

For more information, please see:

Please note comments are due by February 29, 2008.


Article by: Michael Herman

On November 27, 2007, Vancouver-based QLT Inc. announced that it has formed a special committee of directors to "review the company's strategic alternatives" which typically means that a company has put itself up for sale.

QLT's lead products are the eye drug Visudyne® and Eligard®, a prostate cancer therapy. QLT went public in 1986 and for a considerable period of time was a high flyer, regarded as one of the top life sciences growth stories in Canada. Its stock traded as high as $45.00 in 2000 before beginning a downward spiral. QLT's shares have fallen more than 50% in the past year alone to a recent low of $3.46 as its financial results have weakened and its products and technologies have failed to meet the expectations of the investment community.

QLT's struggles as a public company over the past few years have been consistent with the performance generally of many publicly traded biotech companies. Most recently, two other Canadian public life science companies, Axcan Pharma Inc. and Aspreva Pharmaceuticals Corporation have announced that they are being sold, Axcan to a US private equity fund and Aspreva to a Swiss-based diversified healthcare market group. In both cases, the purchase price for the companies represented a significant premium over the trading price of their shares on the public markets.

In Canada, public biotech companies have not fared well in 2007. The market capitalization of public Canadian life sciences companies is down by 30% in the first nine months of the year. However, in the US, notwithstanding a slump during the summer months, biotech stocks have performed rather well. At October 31st, 2007 the Burrill Biotech Select Index was up 17.5% for the year, led by companies such as Gilead Sciences and Illumina. The shares of prior year top performers, such as Amgen and Genentech, are down this year, suggesting that the maturing of public US biotech companies is attracting significant investor interest. Stephen Burrill, CEO of Burrill & Company, believes that biotech stocks will continue to improve led by new emerging and elite companies within the sector.

Another sign of improving fortunes for public biotech companies in the US is that at the end of October there had been 26 biotech initial public offerings in the US. While the IPO price for the shares of many of these companies was below the proposed range targeted, most of these new public companies have held their values quite well following their IPO's unlike the experience of many new public biotech companies in recent years.

Canadian public biotech companies have not faired as well as US companies in 2007. It will be interesting to see if the US trend toward rising prices for biotech shares extends to Canadian companies in 2008 or whether the recent pattern of sales of Canadian public biotech companies will continue.

For more information, please see:

EU, US Regulators Ease Process For Orphan Drugs

Article by: Roger Tam

In an effort to encourage development of drug treatments for rare diseases, the European Commission, the European Medicines Agency and the U.S. Food and Drug Administration announced steps to streamline the application process for orphan drugs. Companies will be able to simultaneously apply in both jurisdictions using one application.

The U.S. Orphan Drug Act defines a "rare disease or condition" in the case of a drug to mean any disease or condition which a) affects less than 200,000 persons in the U.S; or b) affects more than 200,000 people in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for such disease or condition will be recovered from sales in the U.S. of such drug. In the EU, low prevalence is taken as less than 5 per 10,000 people in the EU. There are estimated to be between 5000 and 8000 such diseases today.

For more information, please see:

Alliance Proposes New Wait Time Benchmarks

Article by: Marc Richard

A coalition of physician associations is pressing provincial governments to expand previously established wait time benchmarks to cover additional specialties. The Wait Time Alliance has proposed new benchmarks for emergency care, psychiatric care, plastic surgery, gastroenterology and anaesthesiology in a new report. The Alliance is hoping the provincial governments will announce initiatives to apply these benchmarks by the end of the year.

For more information, please see:

Health Canada Update Notice On Registration And Disclosure Of Clinical Trial Information

Article by: Jennifer Wilkie

On November 30, 2007, Health Canada posted a notice to provide an update on Health Canada's initiative on the registration and disclosure of clinical trial information for products such as drugs and medical devices. The notice indicates that Health Canada is currently considering development of regulatory requirements for registration of clinical trials and disclosure of results. However, in the meantime Health Canada is encouraging sponsors to register their clinical trials within 21 days of the commencement of a clinical trial using one of the WHO's register networks: the ( or Current Controlled Trials International Standard Randomised Controlled Trials Number Register (

Health Canada is considering the creation of a Canadian search portal for clinical trials. The notice indicates that since the initiative was launched, Health Canada has conducted extensive consultations and has received a strong consensus among stakeholders that a Canadian approach should be consistent with the international direction. Further, the notice states that if a decision is made to proceed with the regulatory requirements, there will be further opportunity for stakeholders to provide feedback on the issues such as timing of registration, the registration of early phase trials and disclosure of clinical trial results.

The full text of this notice can be found at:

Update On The Comprehensive Review Of The Special Access Programme

Article by: Jennifer Wilkie

Health Canada recently updated their web site to provide comments on their ongoing comprehensive review of the Special Access Programme (SAP). The review of the SAP is said to consist of three sub-projects, namely an operational review to evaluate how SAP is functioning within the existing framework, an ethics review of the mandate and activities of the SAP and a broader policy/regulatory review.

Preliminary consultations occurred in June 2007 soliciting views from users of SAP in two sessions. A consequence of this has been the preparation of an issue identification paper. The issue identification paper sets out a brief history of the development of SAP and attempts to identify issues that may warrant change. A second phase of the review is to obtain comments on the issue identification paper. A third phase of consultation will begin in spring 2008 after the development of an options analysis paper resulting from the second phase consultations.

For more information, please see:

Also, to review the SAP issue identification paper, please see:

Please note comments are due by December 17, 2007.

Recent Cases

Article by: Beverley Moore

Sanofi-Aventis v. Riva, preliminary motion to dismiss a judicial review proceeding; November 7, 2007, drug: rampiril.

The Minister of Health had sent a letter to the generic company indicating that once it had satisfied the requirements of the NOC Regulations, it would be eligible to receive a NOC regardless of whether the other generic company to which it had cross-referenced its submission had satisfied all of the NOC Regulations and received a NOC. The innovator sought to judicially review the decision in the letter.

The Court held that the letter from the Minister was not a "decision" in a sense that it could not be judicially reviewed.

The Court also held that if the letter was a decision, the innovator company did not have standing as it is not directly affected by the letter. Although the innovator's commercial interest could be affected, the commercial advantage conferred on the third party by the government does not give rise to standing to commence a judicial review application.

The full text of the decision can be found at:

Purdue v. Pharmascience, interlocutory motion on a section 55.2 proceeding;
November 15, 2007, drug: oxycodone

The Applicants brought a motion to reverse the order of evidence in the s.55.2 proceeding.

The Court found that it did have the discretion, in the context of case management, to vary the order in which evidence of the parties on an Application is to be served and filed, if it is necessary for the just, most expeditious and least expensive determination of the proceedings on the merits.

The Court saw the most potential for narrowing the issues and gaining efficiencies with respect to allegations of invalidity. The Court also found that if the generic company filed its evidence first it would serve to substantially narrow the issues to be litigated in the matter and it would be likely that far fewer expert reports would be needed. This in turn would limit the risk that reply would be sought or allowed and it would shorten the time frame necessary cross-examinations due to the busy schedule of experts.

However, in this case there was an issue relating to an alleged lack of sound prediction in the patent. The innovator agreed it would likely have to file factual affidavits from the inventors in response to this allegation. Thus, the motion was dismissed.

The full text of the decision can be found at:

Servier v. Apotex, interlocutory motion in an infringement action;
November 19, 2007, drug: perindopril

By this motion, two additional innovator companies sought leave to be added as defendants to Apotex' counterclaim against Servier under the Competition Act. Apotex alleged that Servier entered into a conspiracy with the two innovator companies and agreed to allocate amongst themselves certain patent claims that were the subject of a conflict proceeding between those parties. Apotex has made very similar allegations in a counterclaim under the Competition Act in a separate action involving the two innovator companies. Apotex and Servier opposed the motion.

The Court denied the motion. Plaintiffs are allowed to choose the defendants against whom they wish to proceed. The test is stringent to add a party to a proceeding. The Court found that the two additional parties would not be bound by the results of this action, as there is nothing in the jurisprudence or the Competition Act which indicates that establishing the elements of the conspiracy for one defendant relieves the burden on the plaintiff in any way in subsequent proceedings against another party on the same conspiracy.

The full text of the decision can be found at:

Apotex v. The Gov. in Council et al.; The Minister of Health et al. v. CGPA, appeal of decisions on motions to strike judicial reviews; November 27, 2007

In a pair of decisions, the Court of Appeal has indicated that judicial review applications brought by CGPA and Apotex attacking the vires of the Data Protection Regulations brought into force in October 2006 may be heard.

In a first appeal, Apotex was successful in overturning the decision of the motions judge who had found that Apotex did not have standing and struck out Apotex' application. The Court of Appeal found that the question of standing was subsumed in the motion to strike test and that for the purposes of the motion to strike, it was not plain and obvious that Apotex was not directly affected by the Data Protection Regulations and therefore allowed the appeal. The Court comments however that it will be up to the trial judge ultimately to consider the issue of standing.

In a second appeal, the Attorney General had sought to overturn a motions judge's decision finding that the Motion to Strike should be dismissed. The appeal was dismissed. The Court of Appeal found that the motions judge did not proceed on a wrong principle of law in finding the application should not be struck as it was not plain and obvious that the CGPA did not have public standing. Accordingly, these two proceedings may now proceed.

The full text of these decision can be found at:,

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions